Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of 1 of the following:
• •* Ovarian epithelial adenocarcinoma
• •* Fallopian tube cancer
• •* Peritoneal cavity cancer
• •Recurrent or persistent disease after no more than 2 prior treatment regimens (1 regimen for primary disease and/or 1 regimen for recurrent disease)
• •Platinum-resistant disease, defined as 1 of the following:
• •* Treatment-free interval \< 6 months after platinum-based therapy
• •* Disease progression during platinum-based therapy
• •Measurable disease by physical exam, chest x-ray, CT scan, or MRI
• •No brain metastases
• •PATIENT CHARACTERISTICS:
• •Gynecologic Oncology Group performance status 0-2
• •Life expectancy \> 6 months
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Hemoglobin ≥ 8 g/dL
• •Creatinine clearance ≥ 50 mL/min
• •Bilirubin normal
• •AST or ALT and alkaline phosphatase (AP) meeting 1 of the following criteria:
• •* AST or ALT ≤ 5 times upper limit of normal (ULN) AND AP normal
• •* AST or ALT ≤ 1.5 times ULN AND AP ≤ 2.5 times ULN
• •* AST or ALT normal AND AP ≤ 5 times ULN
• •No peripheral neuropathy \> grade 2
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 6 months after completion of study treatment
• •No other concurrent malignancy except for curatively treated nonmelanoma skin cancer
• •No prior invasive malignancy \< 5 years after curative therapy
• •No serious uncontrolled medical or psychiatric illness that would preclude study participation or limit survival to \< 6 months
• •No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 or to fluoropyrimidine therapy or fluorouracil
• •No inability to tolerate oral medication due to bowel obstruction, lack of physical integrity of the upper gastrointestinal tract, inability to swallow, or malabsorption syndrome
• •No serious concurrent infections
• •No clinically significant cardiac disease not well controlled with medication, including any of the following:
• •* Congestive heart failure
• •* Symptomatic coronary artery disease
• •* Symptomatic cardiac arrhythmias
• •* Myocardial infarction within the past 12 months
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •No prior docetaxel or capecitabine or other fluoropyrimidine therapy
• •Recovered from prior therapy
• •At least 2 weeks since prior major surgery
• •At least 4 weeks since prior chemotherapy, hormone therapy, or radiotherapy
• •No other concurrent chemotherapeutic agents, biological therapy, radiotherapy, or other investigational agents